摘要
目的 旨在探讨既往免疫经治的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受安罗替尼联合PD-1单抗治疗方案的疗效和安全性。方法 纳入临床实践中接受安罗替尼联合PD-1单抗治疗的既往免疫经治的52例晚期NSCLC患者。安罗替尼为临床常规用法用量,PD-1单抗为目前已经在中国上市的PD-1单抗,包括信迪利单抗,卡瑞利珠单抗和帕博利珠单抗。回顾性地收集患者治疗过程中的疗效及安全性数据,并对患者进行定期的随访获取长期生存的数据。结果 最佳的疗效结果提示接受安罗替尼联合PD-1单抗治疗的既往免疫经治的晚期NSCLC患者中取得部分缓解患者12例,疾病稳定患者32例,疾病进展患者8例。因此,该方案的客观缓解率为23.1%(95%CI:12.5%~36.8%),疾病控制率为84.6%(95%CI:71.9%~93.1%)。中位无进展生存期为6.3个月(95%CI:2.64~9.96),中位的总生存期为16.6个月(95%CI:8.08~25.12)。既往免疫相关方案不耐受的患者(10例)接受该方案治疗时具有相对较好的预后(中位OS:23.4个月vs. 11.5个月,P=0.034)。安全性分析结果提示在接受安罗替尼联合PD-1单抗的总体不良反应安全可控。结论 在既往免疫经治的晚期NSCLC患者中安罗替尼联合PD-1单抗的治疗方案具有潜在的疗效和较好的安全性。既往免疫相关方案不耐受的患者可能从该方案中获益。研究结论尚需要大样本研究进一步验证。
Objective This study aimed to investigate the efficacy and safety of anlotinib plus PD⁃1 blockades in patients with advanced non⁃small cell lung cancer(NSCLC)previously treated with immunotherapy.Methods A total of 52 patients with advanced NSCLC previously treated with immunotherapy who had received anlotinib plus PD⁃1 blockades were included in this study.Anlotinib was administered with the conventional usage and dosage,and PD⁃1 blockades were available in China,including sintilimab,camrelizumab and pembrolizumab.The data on the efficacy and safety were retrospectively collected during treatment with anlotinib plus PD⁃1 block⁃ades and all the patients were followed up regularly to assess the long⁃term survival.Results The best overall response suggested that 12 of the advanced NSCLC patients with previous immunotherapy who received anlotinib plus PD⁃1 blockades achieved partial response,32 were stable,and 8 were progressive,revealing an objective response rate of 23.1%(95%CI:12.5%~36.8%)and a disease control rate of 84.6%(95%CI:71.9%~93.1%).The median progress⁃free survival(PFS)was 6.3 months(95%CI:2.64~9.96),the median overall survival(OS)was 16.6 months(95%CI:8.08~25.12).10 patients intolerant to the previous immune⁃related regimens obtained a relatively better prognosis when they received this regimen(median OS:23.4 months vs.11.5 months,P=0.034).Safety profile suggested that the overall adverse reactions related to anlotinib combined with PD⁃1 blockades were safe and controllable.Conclusions Anlotinib plus PD⁃1 blockades demonstrated potential efficacy and tolerable toxicity among the advanced NSCLC patients previously treated with immunotherapy.Those intolerant to the previ⁃ous immune⁃related regimens might benefit from this regimen.The finding of this paper need to be further verified via large sample studies.
作者
武阳
陆翰杰
水会锋
WU Yang;LU Hanjie;SHUI Huifeng(Department of Oncology,Luoyang Central Hospital,Luoyang 471000,China)
出处
《实用医学杂志》
CAS
北大核心
2023年第5期572-578,共7页
The Journal of Practical Medicine
基金
洛阳市中心医院新技术评审项目(编号:XJSPS037)。
